FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

1

The FDA approved orforglipron (Foundayo), a once-daily oral GLP-1 receptor agonist for chronic weight management in adults with obesity.
2

In the ATTAIN-1 trial, patients on the highest dose lost an average of 27.3 pounds, significantly more than the placebo group.
3

Orforglipron also reduced cardiometabolic risk markers, including waist circumference and triglycerides.
4

Safety warnings include potential thyroid tumors; it is contraindicated in patients with specific thyroid cancer histories.
5

Orforglipron will be available through LillyDirect, with pricing options for eligible patients starting at $25 per month.

1